|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM199304556 |
| 003 |
DE-627 |
| 005 |
20231223214347.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2010 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2010.06.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0664.xml
|
| 035 |
|
|
|a (DE-627)NLM199304556
|
| 035 |
|
|
|a (NLM)20599429
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Johnson, Trina A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients
|
| 264 |
|
1 |
|c 2010
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.12.2010
|
| 500 |
|
|
|a Date Revised 17.03.2022
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2010 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a FTY720 (Fingolimod) reduces multiple sclerosis disease activity by inducing lymphopenia and inhibiting lymphocyte re-entry from lymph nodes. Peripheral lymphocyte reconstitution following drug discontinuation has been considered relatively rapid (2-4 weeks), based on short-term studies. We investigated the kinetics of lymphocyte reconstitution in MS patients in open label extension phases of FTY720 clinical trials who discontinued therapy after prolonged use (>1-5 years), and examined histological features of a mediastinal lymph node obtained from a lymphopenic FTY720 patient. Although three patients showed reconstitution of peripheral lymphocytes within the predicted timeline, two patients continued to be lymphopenic 9 and 34 months after therapy cessation. Lymph nodes from the latter patient showed preserved architecture. Notwithstanding preserved lymph node integrity, time for lymphocyte reconstitution after prolonged FTY720 therapy can be significantly greater than predicted by shorter-term studies. This is relevant for clinical decisions regarding management of patients using this therapy and for introducing alternate therapies
|
| 650 |
|
4 |
|a Clinical Trial, Phase II
|
| 650 |
|
4 |
|a Clinical Trial, Phase III
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a CCR7 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Propylene Glycols
|2 NLM
|
| 650 |
|
7 |
|a Receptors, CCR7
|2 NLM
|
| 650 |
|
7 |
|a Fingolimod Hydrochloride
|2 NLM
|
| 650 |
|
7 |
|a G926EC510T
|2 NLM
|
| 650 |
|
7 |
|a Sphingosine
|2 NLM
|
| 650 |
|
7 |
|a NGZ37HRE42
|2 NLM
|
| 700 |
1 |
|
|a Shames, Igor
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Keezer, Mark
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lapierre, Yves
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Haegert, David G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bar-Or, Amit
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Antel, Jack
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 137(2010), 1 vom: 17. Okt., Seite 15-20
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:137
|g year:2010
|g number:1
|g day:17
|g month:10
|g pages:15-20
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2010.06.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 137
|j 2010
|e 1
|b 17
|c 10
|h 15-20
|